Brain Amyloid Imaging With Pittsburgh Compound B in Normal Aging, Mild Cognitive Impairment, and Dementia
Description
Brief Summary
This is a prospective, open label, non-therapeutic, diagnostic imaging study. The purpose of
this study is to utilize Pittsburgh Compound B positron emission imaging (PiB PET) to
ascertain the relationship between change in amyloid burden over time, and concurrent change
in clinical status.
Detailed Description
Identification of risk factors and biomarkers of neurodegenerative disease is essential in
caring for the growing numbers of elderly. Imaging biomarkers provide non-invasive ways to
look at brain function. A new PET imaging agent, Pittsburgh Compound B (PiB), that identifies
brain amyloid is an exciting development in brain imaging that needs to be studied. We plan
to study this imaging technique in normal volunteers and patients with a variety of
neurodegenerative diseases to determine its utility. Long term followup of these subjects
will allow us to understand the predictive ability of this new test.
Phase
N/AInclusion and Exclusion Criteria
- Age 30-100
- Subjects who have completed or are scheduled to undergo the neurological evaluation procedures in the Mayo Clinic Study of Aging, Mayo ADRC, or Mayo neurodegenerative disease clinics.
- Subjects unable to lie down without moving for 10 minutes
- Women who are pregnant or cannot stop breast feeding for 24 hours
- Claustrophobic patients unable to tolerate the scans
- Standard safety exclusionary criteria for MRI such as metallic foreign bodies, pacemaker, etc.
Sites
Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.
Powered by
SC CTSI